on Revelation Biosciences, Inc. (NASDAQ:REVB)
Revelation Biosciences Secures Quorum for Upcoming Special Meeting
Revelation Biosciences, Inc. has confirmed a quorum for its Special Meeting slated for December 3, 2025. The company, listed on NASDAQ as REVB, focuses on managing inflammation through its proprietary formulation, Gemini. Revelation encourages shareholders to cast their votes by December 2, 2025.
The company recently shared the successful submission of its end-of-phase 1 meeting package to the FDA. This move is part of their strategy for agency feedback on the development of Gemini as a treatment for acute kidney injury (AKI).
Financial results for the period ending September 30, 2025, were also disclosed, highlighting substantial proceeds of $9.6 million from warrant inducement and key findings from the PRIME clinical study.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Revelation Biosciences, Inc. news